Budweiser Maker AB InBev Stock Sinks as China, Brazil Demand Plunges

AB InBev (BUD) shares fell 12% after second-quarter volume and revenue missed analyst estimates, primarily driven by significant declines in China and Brazil, where volumes dropped over 7% and 6.5% respectively. Despite an overall volume decrease of 1.9% and revenue of $15.00 billion falling short of forecasts, the brewer reported adjusted EPS of $0.98, surpassing estimates, and saw revenue growth across all other global markets, including a 2% rebound in the U.S. CEO Michel Doukeris reiterated confidence in the company's 2025 outlook, acknowledging a 'dynamic operating environment'.

Analysis

Anheuser-Busch InBev reported a mixed second quarter, characterized by significant geographic performance divergence that led to a sharp negative market reaction. While adjusted EPS of $0.98 narrowly beat analyst expectations of $0.96, the company missed on key top-line metrics with revenue of $15.00 billion falling short of the $15.28 billion forecast. The primary driver of this underperformance was a 1.9% decline in overall volume, led by a 2.2% drop in core beer volumes. This weakness was highly concentrated in key emerging markets, with China experiencing a 6% revenue slump on a volume decline exceeding 7%, and Brazil's revenue falling nearly 2% as volumes contracted by 6.5%. In contrast, all other global markets demonstrated revenue growth, most notably a 2% revenue rebound in the U.S. which reversed a 5% decline from the first quarter. Despite the 12% share price drop following the release, management reiterated confidence in its 2025 outlook, and the stock remains up approximately 17% year-to-date.

Key Decisions for Investors

• Investors should closely monitor consumer demand trends and macroeconomic data in China and Brazil, as these two markets are the primary source of current weakness and represent a significant headwind to global volume growth.
• The 2% revenue rebound in the U.S. market is a positive signal of stabilization in a key developed market, and its continued strength should be weighed against the emerging market challenges.
• Given the sharp 12% stock decline, investors may re-evaluate the company's valuation, considering whether the market has fully priced in the regional weaknesses or if it presents a buying opportunity based on management's confidence in its 2025 outlook.